Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
- 39th Annual
J.P. Morgan Healthcare Conference. A presentation and Q&A discussion will take place on Thursday, January 14, 2021at 3:40 p.m. ETand a live webcast may be accessed within the Investors & Media section of the Cyclerion.com website. An archived replay will be available for approximately 90 days following the presentation. H.C. Wainwright BioConnect Conference. An on-demand presentation will be available on Monday January 11, 2021at 6:00 a.m. ETat the conference website.
About Cyclerion Therapeutics
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative medicines for people with serious diseases of the central nervous system (CNS). Cyclerion’s lead program is CY6463 a pioneering CNS-penetrant sGC stimulator in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer's Disease with Vascular pathology (ADv).
Kendall Investor Relations
Source: Cyclerion Therapeutics, Inc.